Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.66 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.66 |
| ▸ | LAP3 | P28838 | 5/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.66 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
| ▸ | ANPEP | P15144 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amphetamine SCHEMBL113682 | 0.89 | TAAR1 (0.76) | LAP3TAAR1SLC6A4SLC6A2MAOA | |
| Dextroamphetamine SCHEMBL547496 | 0.89 | TAAR1 (0.76) | LAP3TAAR1SLC6A4SLC6A2MAOA | |
| Levamfetamine SCHEMBL31637605 | 0.87 | TAAR1 (0.73) | LAP3TAAR1SLC6A4SLC6A2MAOA | |
| Dextroamphetamine SCHEMBL17924971 | 0.87 | TAAR1 (0.73) | LAP3TAAR1SLC6A4SLC6A2MAOA | |
| Amphetamine SCHEMBL16858761 | 0.87 | TAAR1 (0.73) | LAP3TAAR1SLC6A4SLC6A2MAOA | |
| Amphetamine SCHEMBL4387791 | 0.85 | SLC6A4 (0.59) | LAP3TAAR1SLC6A4SLC6A2MAOA | |
| Amphetamine SCHEMBL27775648 | 0.83 | TAAR1 (0.61) | LAP3TAAR1SLC6A4SLC6A2MAOA | |
| Amphetamine SCHEMBL28990193 | 0.81 | TAAR1 (0.91) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Amphetamine SCHEMBL13747801 | 0.81 | SLC6A2 (1.00) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Levamfetamine SCHEMBL9673275 | 0.81 | SLC6A2 (1.00) | TAAR1SLC6A4SLC6A2MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121029-A2 | PRODRUGS AND METHODS OF MAKING AND USING THE SAME | Neurogesx, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080318905-A1 | Prodrugs and methods of making and using the same | NEUROGESX, INC. | 2008-12-25 | — | — | US | disclosed |
| WO-2008070149-A2 | PRODRUGS AND METHODS OF MAKING AND USING THE SAME | NEUROGESX, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318905-A1 | Prodrugs and methods of making and using the same | NAPEPLD, CES2, MTAP | SLC6A2 106/4885SLC6A3 153/4885LAP3 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.